Pinaki Biswas

TL;DR: Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis and the proportion of patients who had achieved an Investigator Global Assessment response was significantly higher in the abrocITinib 100 mg group than in the placebo group.

TL;DR: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD) and laboratory values indicating thrombocytopenia.

TL;DR: Among women with FM, pain symptoms early in the day are associated with variations in function of the hypothalamic-pituitary-adrenal axis, and cortisol levels alone explained 38% and 14% of the variation in pain at the waking and 1 hour time points, respectively.

TL;DR: A recent decision-analytic model for the cost-effectiveness of empirical anticandidal therapy in high-risk ICU patients showed that empirical fluconazole would be reasonable from a cost perspective if the likelihood of invasive candida is greater than 2.5% (24).

TL;DR: In this article, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleucin-13 signaling, was investigated for the treatment of atopic dermatitis.